To revisit the Coeptis deal, which may be replicat

To revisit the Coeptis deal, which may be replicated 3 years later and with altered numbers:

The Company entered into a stock purchase agreement to sell 50%-owned subsidiary Elto Pharma, Inc. to Coeptis Pharma, Inc. (“Coeptis”) in November 2019. Coeptis is currently raising capital to complete the acquisition. Following the acquisition, Amarantus is expected to own approximately 25% of Coeptis.

On December 15th, 2018, the Company entered into the definitive Merger Agreement between Elto Pharma, Inc. and
Coeptis Pharmaceuticals, Inc. Under the terms of the agreement, Coeptis will issue 7.5 million shares of Coeptis
common stock to shareholder of Elto Pharma, Inc., then representing 1/3 of outstanding Coeptis shares outstanding,
in exchange for all of the shares of Elto Pharma, Inc. An additional 7.5 million shares of Coeptis common shares are
issuable upon the earlier of:
1) Successful completion of a Phase 2b trial for eltoprazine in Parkinson’s levodopa-induced dyskinesia;
or
2) New Drug Application approval by US FDA for eltoprazine in any indication.
Key closing conditions for the Elto Pharma, Inc. and Coeptis Pharmaceuticals Merger Agreement include:
1. Payment of Psychogenics, Inc. legal fees by December 31st, 2018;
2. Acquisition of D&O insurance by January 15, 2019;
3. Coeptis raising a minimum of $6M dedicated towards the development of eltoprazine by April 5, 2019.